Table 1.
Baseline characteristics of study population according to detection of MVs in plasma samples collected prior to first-line NNRTI-based ART
| ≥1 IAS MV, N = 55 | No MVs, N = 205 | P | Total, N = 260 | |
|---|---|---|---|---|
| Age (years) | 0.776 | |||
| median (IQR) | 36 (26–41) | 33 (24–43) | 34 (24–42) | |
| Gender, n (%) | 0.050 | |||
| female | 6 (10.9) | 47 (22.9) | 53 (20.4) | |
| Ethnicity, n (%) | 0.143 | |||
| white | 39 (70.9) | 131 (63.9) | 170 (65.4) | |
| black | 3 (5.5) | 6 (2.9) | 9 (3.5) | |
| Asian | 2 (3.6) | 5 (2.4) | 7 (2.7) | |
| other | 11 (20.0) | 63 (30.7) | 74 (28.5) | |
| Mode of HIV transmission, n (%) | 0.382 | |||
| MSM | 27 (49.1) | 77 (37.6) | 104 (40.0) | |
| heterosexual | 13 (23.6) | 82 (40.0) | 95 (36.5) | |
| intravenous drug use | 6 (10.9) | 26 (12.7) | 32 (12.3) | |
| other/unknown | 9 (16.4) | 20 (9.8) | 29 (11.2) | |
| HIV-1 subtype, n (%) | 0.276 | |||
| A | 1 (1.8) | 7 (3.4) | 8 (3.1) | |
| B | 40 (72.7) | 151 (73.7) | 191 (73.5) | |
| C | 3 (5.5) | 10 (4.9) | 13 (5.0) | |
| D | 0 (0.0) | 1 (0.5) | 1 (0.4) | |
| F | 2 (3.6) | 3 (1.5) | 5 (1.9) | |
| G/J | 3 (5.5) | 7 (3.4) | 10 (3.8) | |
| CRF01_AE | 0 (0.0) | 9 (4.4) | 9 (3.5) | |
| CRF01_AG | 4 (7.3) | 6 (2.9) | 10 (3.8) | |
| Calendar year of starting NNRTI | 0.250 | |||
| median (IQR) | 2004 (2002–06) | 2003 (2003–06) | 2003 (2002–06) | |
| Time from sample to ART initiation (months) | 0.310 | |||
| median (IQR) | 2 (0–4) | 2 (0–4) | 2 (0–4) | |
| CD4+ count at ART initiation (cells/mm3) | 0.717 | |||
| median (IQR) | 261 (196–326) | 258 (173–371) | 259 (176–353) | |
| HIV-1 RNA at ART initiation (log10 copies/mL) | 0.995 | |||
| median (IQR) | 4.92 (4.55–5.36) | 4.90 (4.49–5.32) | 4.91 (4.58–5.33) | |
| NNRTI started, n (%) | 0.962 | |||
| nevirapine | 9 (16.4) | 33 (16.1) | 42 (16.2) | |
| efavirenz | 46 (83.6) | 172 (83.9) | 218 (83.8) | |
| NRTI pair started, n (%) | 0.040 | |||
| recommended: ABC/3TC or TDF/FTC | 19 (34.5) | 62 (30.2) | 81 (31.2) | |
| alternative: ZDV/3TC or TDF/3TC | 26 (47.3) | 106 (51.7) | 132 (50.8) | |
| not recommended | 10 (18.2) | 37 (18.0) | 47 (18.1) | |
| Cohort, n (%) | 0.340 | |||
| Arevir | 0 (0.0) | 6 (2.9) | 6 (2.3) | |
| Aquitaine | 3 (5.5) | 25 (12.2) | 28 (10.8) | |
| EuroSIDA | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| ICONA | 11 (20.0) | 40 (19.5) | 51 (19.6) | |
| KompNet | 5 (9.1) | 9 (4.4) | 14 (5.4) | |
| RFH | 12 (21.8) | 48 (23.4) | 60 (23.1) | |
| Swiss HIV Cohort Study | 24 (43.6) | 77 (37.6) | 101 (38.8) |
IAS-USA, IAS-USA HIV-1 drug resistance mutation list (March 2013 update); ABC, abacavir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; FTC, emtricitabine; ZDV, zidovudine.